This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This gives you plenty of time to catch up on any sessions you missed, revisit important topics, and complete your CME requirements. How Do I Claim CME Credit? Claiming your CME credit is simple. Congratulations on earning your CME credits—well done! How Do I Access CMHC On-Demand? Getting started is easy.
Neha Agarwal, PhD, Clinical Director at Cardiometabolic Health Congress , Informa Connect, recently presented significant findings at the 84th American Diabetes Association (ADA) Scientific Sessions. Competence in selecting treatments for long-term obesity management rose from 43% pre-test to 95% post-test.
The focus will be on the intricate interplay between cardiorenal and metabolic conditions, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, driven by lifestyle and health factors. Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. When I heard of his passing, I felt quite sad.
Black History Month is a poignant backdrop to the alarming rise in obesity and type 2 diabetes, particularly among those of marginalized populations. Two major risk factors for CVD are hypertension and diabetes, which also place a heavier burden on minority groups.
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations. After the reception, many attendees enjoyed dinner at the PME (Non-CME) Dinner Symposium or ventured to one of Boston’s trendy Back Bay eateries. Experts like Louis J.
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
A vast collection of webinars, CME activities, expert interviews, on-demand event recordings, news articles, drug pipelines, and many other resources are now grouped into areas of specialty focus. For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity.
SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity. Earn 14 CME credits anytime on any device. Read the published study. Access the full study. Co-chaired by leading experts Peter Libby, MD , Erin D.
cardiometabolic health CME/CE conference: the 19th Annual CMHC. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors.
November is National Diabetes Month , and with the increasing overlap between type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH) , it’s critical to focus on integrating liver health into the management of cardiometabolic patients.
Healthcare professionals should consider pharmacotherapy options that address T2D, obesity, and liver disease: Statins : Statins are first-line therapies for managing dyslipidemia and reducing cardiovascular risk in patients with MASH. This dual action makes tirzepatide a promising option for treating MASH in patients with T2D and obesity.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content